In a retrospective multinational study, lymphoid-directed therapy was superior to myeloid-directed therapy for most pediatric patients with mixed-phenotype acute leukemias, except for a minority of patients with CD19-negative leukemia, who benefitted from myeloid-directed therapy [56]. This evidence concerns the gene CD19 and leukemia.